In vivo targeting of HER2-positive tumor using 2-helix affibody molecules

Amino Acids

Volumn 43, Issue 1, 2012, Pages 405-413

  Ren, Gang ^a   Webster, Jack M ^b   Liu, Zhe ^a   Zhang, Rong ^b   Miao, Zheng ^a   Liu, Hongguang ^a   Gambhir, Sanjiv S ^a   Syud, Faisal A ^b   Cheng, Zhen ^a  

^a STANFORD UNIVERSITY   (United States)

^b GENERAL ELECTRIC COMPANY   (United States)

Author keywords

111In; 64Cu; Affibody; HER2; Molecular imaging; PET

Indexed keywords

COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; INDIUM 111; MUT DS PROTEIN; TETRAXETAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; IN VIVO STUDY; ISOTOPE LABELING; LIVER; MOLECULAR PROBE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; BINDING SITES; BREAST NEOPLASMS; COPPER RADIOISOTOPES; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; INDIUM RADIOISOTOPES; MICE; MICE, NUDE; MOLECULAR MIMICRY; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEINS; RECEPTOR, ERBB-2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSPLANTATION, HETEROLOGOUS;

MUS; MUS MUSCULUS;

EID: 84862756658     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-1096-7     Document Type: Article

References (46)

1. S Ahlgren H Wallberg TA Tran C Widstrom M Hjertman L Abrahmsen, et al. 2009 Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine J Nucl Med 50 781 789 19372467 10.2967/jnumed.108.056929 1:CAS:528: DC%2BD1MXmtV2hsrw%3D
2. Andersen JT, Pehrson R, Tolmachev V, Bekele MD, Abrahmsen L, Ekblad C (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain (ABD). J Biol Chem
3. CA Boswell X Sun W Niu GR Weisman EH Wong AL Rheingold, et al. 2004 Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes J Med Chem 47 1465 1474 14998334 10.1021/jm030383m 1:CAS:528:DC%2BD2cXhtFagtLw%3D (Pubitemid 38327472)
4. A Capello EP Krenning WA Breeman BF Bernard M de Jong 2003 Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide J Nucl Med 44 98 104 12515882 1:CAS:528:DC%2BD3sXps1CqsQ%3D%3D (Pubitemid 36077719)
5. 18F-labeled protein scaffold molecules J Nucl Med 49 804 813 18413392 10.2967/jnumed.107.047381 1:CAS:528: DC%2BD1cXmvVSju7o%3D (Pubitemid 351717547)
6. F Ciardiello G Tortora 2008 EGFR antagonists in cancer treatment N Engl J Med 358 1160 1174 18337605 10.1056/NEJMra0707704 1:CAS:528:DC%2BD1cXjt1ahsL4%3D (Pubitemid 351398490)
7. EC Dijkers JG Kosterink AP Rademaker LR Perk GA van Dongen J Bart, et al. 2009 Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging J Nucl Med 50 974 981 19443585 10.2967/jnumed.108. 060392 1:CAS:528:DC%2BD1MXnvF2ru7s%3D
8. T Ekblad T Tran A Orlova C Widstrom J Feldwisch L Abrahmsen, et al. 2008 Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake Eur J Nucl Med Mol Imaging 35 2245 2255 18594815 10.1007/s00259-008-0845-7 1:CAS:528:DC%2BD1cXhsVyls73J
9. Ellison D, Kaufman J, Mather SJ (2010) Automated radiolabelling of monoclonal antibodies with the Modular Lab system. Nucl Med Commun 31:173-177
10. RH Engel VG Kaklamani 2007 HER2-positive breast cancer: current and future treatment strategies Drugs 67 1329 1341 17547474 10.2165/00003495- 200767090-00006 1:CAS:528:DC%2BD2sXptVyku7s%3D (Pubitemid 46879097)
11. G Ferretti A Felici P Papaldo A Fabi F Cognetti 2007 HER2/neu role in breast cancer: from a prognostic foe to a predictive friend Curr Opin Obstet Gynecol 19 56 62 17218853 10.1097/GCO.0b013e328012980a (Pubitemid 46095874)
12. B Glisson AD Colevas R Haddad J Krane A El-Naggar M Kies, et al. 2004 HER2 expression in salivary gland carcinomas: dependence on histological subtype Clin Cancer Res 10 944 946 14871971 10.1158/1078-0432.CCR-03-0253 1:CAS:528:DC%2BD2cXhtFCnsLo%3D (Pubitemid 38198894)
13. M Gotthardt J van Eerd-Vismale WJ Oyen M de Jong H Zhang E Rolleman, et al. 2007 Indication for different mechanisms of kidney uptake of radiolabeled peptides J Nucl Med 48 596 601 17401097 10.2967/jnumed.106.036020 1:CAS:528:DC%2BD2sXhtVert7nF (Pubitemid 47571416)
14. C Gravalos A Jimeno 2008 HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann Oncol 19 1523 1529 18441328 10.1093/annonc/mdn169 1:STN:280:DC%2BD1crivFajtQ%3D%3D
15. M Harries I Smith 2002 The development and clinical use of trastuzumab (Herceptin) Endocr Relat Cancer 9 75 85 12121832 10.1677/erc.0.0090075 1:CAS:528:DC%2BD38XntVeqs74%3D (Pubitemid 34832161)
16. G Kramer-Marek DO Kiesewetter J Capala 2009 Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules J Nucl Med 50 1131 1139 19525458 10.2967/jnumed.108.057695 1:CAS:528:DC%2BD1MXpsV2gsb0%3D
17. G Lazaridis G Pentheroudakis N Pavlidis 2008 Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety Crit Rev Oncol Hematol 66 31 41 17766143 10.1016/j.critrevonc.2007.07.002 (Pubitemid 351324127)
18. MR McDevitt D Chattopadhyay JS Jaggi RD Finn PB Zanzonico C Villa, et al. 2007 PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice PLoS One 2 e907 17878942 10.1371/journal.pone.0000907 (Pubitemid 351445315)
19. McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ et al (2009) Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med
20. K McLarty B Cornelissen Z Cai DA Scollard DL Costantini SJ Done, et al. 2009 Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts J Nucl Med 50 1340 1348 19617342 10.2967/jnumed.109.062224 1:CAS:528:DC%2BD1MXhtVymtrrF
21. Miao Z, Ren G, Liu H, Jiang L, Webster JM, Zhang R et al (2011) A Novel 18F-Labeled 2-Helix Small Protein for PET Imaging of HER2 Positive Tumor. Eur J Nucl Med Mol Imaging (Submitted)
22. AB Mitra VV Murty M Pratap P Sodhani RS Chaganti 1994 ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix Cancer Res 54 637 639 7905784 1:CAS:528:DyaK2cXhs1SgsL0%3D (Pubitemid 24068315)
23. R Nanda 2007 Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions Rev Recent Clin Trials 2 111 116 18473995 10.2174/157488707780599375 1:CAS:528:DC%2BD2sXms1Oisr0%3D (Pubitemid 46773878)
24. G Niu Z Li Q Cao X Chen 2009 Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA- trastuzumab Eur J Nucl Med Mol Imaging 36 1510 1519 19440708 10.1007/s00259-009-1158-1 1:CAS:528:DC%2BD1MXps1CktrY%3D
25. PA Nygren 2008 Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold Febs J 275 2668 2676 18435759 10.1111/j.1742-4658.2008.06438.x 1:CAS:528:DC%2BD1cXnt1CjsrY%3D (Pubitemid 351678678)
26. PA Nygren A Skerra 2004 Binding proteins from alternative scaffolds J Immunol Methods 290 3 28 15261569 10.1016/j.jim.2004.04.006 1:CAS:528: DC%2BD2cXlslyhur4%3D (Pubitemid 38922856)
27. A Orlova M Magnusson T Eriksson M Nilsson B Larsson I Hoiden-Guthenberg, et al. 2006 Tumor imaging using a picomolar affinity HER2 binding affibody molecule Cancer Res 66 4339 4348 16618759 10.1158/0008-5472.CAN-05-3521 1:CAS:528:DC%2BD28XjsFSltbs%3D
28. A Orlova H Wallberg S Stone-Elander V Tolmachev 2009 On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model J Nucl Med 50 417 425 19223403 10.2967/jnumed.108.057919 1:CAS:528: DC%2BD1MXktVynsro%3D
29. AF Prasanphanich PK Nanda TL Rold L Ma MR Lewis JC Garrison, et al. 2007 [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues Proc Natl Acad Sci USA 104 12462 12467 17626788 10.1073/pnas.0705347104 1:CAS:528: DC%2BD2sXos1ehtLw%3D (Pubitemid 47206160)
30. G Ren R Zhang Z Liu JM Webster Z Miao SS Gambhir, et al. 2009 A 2-helix small protein labeled with 68 Ga for PET imaging of HER2 expression J Nucl Med 50 1492 1499 19690041 10.2967/jnumed.109.064287 1:CAS:528:DC%2BD1MXhtFOrtbvJ
31. A Serrano-Olvera A Duenas-Gonzalez D Gallardo-Rincon M Candelaria J De la Garza-Salazar 2006 Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer Cancer Treat Rev 32 180 190 16483720 10.1016/j.ctrv.2006.01.001 1:CAS:528:DC%2BD28XjvFSgtro%3D
32. P Smith-Jones D Solit T Akhurst F Afroze N Rosen S Larson 2004 Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors Nat Biotechnol 22 701 706 15133471 10.1038/nbt968 1:CAS:528:DC%2BD2cXksV2gtrs%3D (Pubitemid 38702826)
33. C Swanton A Futreal T Eisen 2006 Her2-targeted therapies in non-small cell lung cancer Clin Cancer Res 12 4377s 4383s 16857814 10.1158/1078-0432.CCR- 06-0115 1:CAS:528:DC%2BD28XntFSmsbk%3D (Pubitemid 44197185)
34. (111)In-trastuzumab (Herceptin) Fab fragments Nucl Med Biol 32 51 58 15691661 10.1016/j.nucmedbio.2004.08.003 1:CAS:528:DC%2BD2MXhtVyisbc%3D (Pubitemid 40187381)
35. Tokuda Y, Suzuki Y, Saito Y, Umemura S (2009) The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review. Breast Cancer
36. V Tolmachev 2008 Imaging of HER-2 overexpression in tumors for guiding therapy Curr Pharm Des 14 2999 3019 18991715 10.2174/138161208786404290 1:CAS:528:DC%2BD1MXmt1ehtA%3D%3D
37. HER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors J Nucl Med 47 846 853 16644755 1:CAS:528:DC%2BD28XltFaiu74%3D (Pubitemid 46772889)
38. V Tolmachev A Orlova FY Nilsson J Feldwisch A Wennborg L Abrahmsen 2007 Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy Expert Opin Biol Ther 7 555 568 17373906 10.1517/14712598.7.4.555 1:CAS:528:DC%2BD2sXjt1yns78%3D (Pubitemid 46524679)
39. 177Lu-labeled HER2-specific Affibody molecule Cancer Res 67 2773 2782 17363599 10.1158/0008-5472.CAN-06-1630 1:CAS:528:DC%2BD2sXivV2nsLk%3D (Pubitemid 46548966)
40. V Tolmachev M Friedman M Sandstrom T Eriksson D Rosik M Hodik, et al. 2009 Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry J Nucl Med 50 274 283 19164241 10.2967/jnumed.108.055525
41. HER2:342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors Bioconjug Chem 18 1956 1964 17944527 10.1021/bc7002617 1:CAS:528:DC%2BD2sXhtF2gsrvF (Pubitemid 350219996)
42. HER2:342-pep2: implications for development of labeled tracers Cancer Biother Radiopharm 23 435 442 18771347 10.1089/cbr.2008.0464 1:CAS:528:DC%2BD1cXhtVOmurnE
43. H Wallberg S Ahlgren C Widstrom A Orlova 2009 Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors Mol Imaging Biol 12 54 62 19557480 10.1007/s11307-009-0238-8
44. JM Webster R Zhang SS Gambhir Z Cheng FA Syud 2009 Engineered two-helix small proteins for molecular recognition Chembiochem 10 1293 1296 19422008 10.1002/cbic.200900062 1:CAS:528:DC%2BD1MXmtlOlsr0%3D
45. Y Yarden BZ Shilo 2007 SnapShot: EGFR signaling pathway Cell 131 1018 18045542 10.1016/j.cell.2007.11.013 (Pubitemid 350138094)
46. S Yeh HK Lin HY Kang TH Thin MF Lin C Chang 1999 From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells Proc Natl Acad Sci USA 96 5458 5463 10318905 10.1073/pnas.96.10.5458 1:CAS:528: DyaK1MXjtFCnsLY%3D (Pubitemid 29234639)